Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial

NCT02704520 · clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
441
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Imperial College London